Amlodipine/valsartan: Fixed-dose combination in hypertension

Drugs

Volumn 68, Issue 3, 2008, Pages 373-381

  Plosker, Greg L ^a   Robinson, Dean M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Amlodipine valsartan, general; Hypertension; Research and development

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ATENOLOL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; VALSARTAN;

BLOOD PRESSURE; CLINICAL TRIAL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; HYPERTENSION; TETRAZOLES; VALINE;

EID: 38949199468     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868030-00008     Document Type: Review

References (31)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-72
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-87
3. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multientre randomised controlled trial. Lancet 2005 Sep 10; 366 (9489): 895-906
4. European Medicines Agency (EMEA). Summary of product characteristics: Exforge® (amlodipine/valsartan) film-coated tablets [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Aug 13]
5. Novartis. Exforge® (amlodipine and valsartan) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2007 Apr [online]. Available from URL: http://www.pharma.us.novartis.com [Accessed 2007 Sep 14]
6. Top C, Cingözbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30 (1): 15-20
7. Ram CVS, Ames RP, Applegate WB, et al. Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Clin Cardiol 1994; 17: 251-6
8. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64 (22): 2537-65
9. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertenisve drugs: a network meta-analysis. Lancet 2007 Jan 20; 369: 201-7
10. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotenisn receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46 (5): 821-6
11. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. STAR Investigators. Diabetes Care 2006; 29: 2592-7
12. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50 (3): 560-86
13. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54 (2): 299-311
14. Thürmann PA. Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 2000 Jan; 1 (2): 337-50
15. Maeda T, Kato M, Tajima A, et al. Additive effect of valsartan on exercise tolerance in hypertensive patients treated with amlodipine [abstract no. PO4-154]. J Hypertens 2006 Dec 1; 24 Suppl. 6: 399
16. Fogari R, Preti P, Mugellini A, et al. Valsartan amlodipine combination and prevention of atrial fibrillation recurrence in hypertensive diabetic patients [abstract no. 3695]. Circulation 2006 Oct 31; 114 (18 Suppl. II): 789-90
17. de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens 2007 Mar; 9 (3): 168-78
18. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Hypertension 2006; 48: 374-84
19. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004 Nov 10; 292 (18): 2217-26
20. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10
21. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. CAFE Investigators. Circulation 2006; 113: 1213-25
22. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Valsartan Heart Failure Trial (Val-HeFT) Investigators. N Engl J Med 2001 Dec 6; 345 (23): 1667-75
23. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363: 2022-31
24. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure trial (Val-HeFT). Am Heart J 2005; 149: 548-57
25. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 Apr 28; 369: 1431-9
26. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Valsartan in Acute Myocardial Infarction (VALIANT) Trial Investigators. N Engl J Med 2003 Nov 13; 349 (20): 1893-906
27. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 Apr; 29 (4): 563-80
28. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007 May; 9 (5): 355-64
29. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy (EX-FAST) study. J Clin Hypertens. Epub 2008 Feb
30. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007 Mar; 21 (3): 220-4
31. Poldermans D, Glazer R, Karagianniss S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007 Feb; 29 (2): 279-89